Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials

Celgene's Ozanimod Reduces Relapses and Brain Volume Loss in MS Patients in Phase III Trials

Source: 
CP Wire
snippet: 

Celgene Corporation (NASDAQ:CELG) announced  on 4/24/18 additional phase III data analyses evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1P1) and 5 (S1P5) receptor modulator, versus interferon beta-1a (IFN β-1a) (Avonex®) in patients with relapsing multiple sclerosis (RMS).